

Supplementary Information

Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – January 2023

Eero Poukka, Sirkka Goebeler, Hanna Nohynek, Tuija Leino, Ulrike Baum

Table S1: Highly predisposing comorbidities or medical therapies	2
Table S2: Moderately predisposing comorbidities or medical therapies	3
Table S3: Enrollment of the study cohorts	4
Table S4: Distribution of baseline characteristics	5
Table S5: Hazard ratios, 65-to-120-year-olds	6
Table S6: Hazard ratios, 65-to-120-year-olds, age-stratified	7
Table S7: Hazard ratios, 65-to-120-year-olds, by vaccine composition	8
Table S8: Hazard ratios, 18-to-64-year-olds with underlying medical conditions	9
Figure S1: Distribution of sequenced Omicron lineages in Finland	10

Table S1: Highly predisposing comorbidities or medical therapies Definition of comorbidities and medical therapies that were considered highly predisposing to severe COVID-19.

Classification system	Codes
Actively treated cancer	
ICD10	C00, C01, C02, C03, C04, C05, C06, C07, C08, C09, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C59, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C83, C84, C85, C86, C87, C88, C89, C90, C91, C92, C93, C94, C95, C96, C97, D051, D39
Down syndrome	
ICD10	Q90
Organ or stem cell transplantation	
ICD10	T86, Z94
Severe chronic respiratory disease	
ICD10	E84, J41, J42, J43, J44, J45, J46, J47, Z902
ICPC2	R96
Severe disorder of the immune system	
ICD10	D7081, D7089, D80, D81, D82, D83, D84, E3100, E723, E76, E791, E792, E798, E799, Q7782, Q7800, Q7808, Q809, Q8900, Q8933, Q8934, Q938, Z908
NCSP	JMA
Severe kidney disease	
ICD10	E102, E112, E142, I12, I13, N00, N01, N02, N03, N04, N05, N07, N08, N11, N14, N18, N19
Type 2 diabetes mellitus	
ATC	A10B
ICD10	E11, E13, E14
ICPC2	T90

ATC, Anatomical Therapeutic Chemical Classification System;

ICD10, International Statistical Classification of Diseases, tenth revision;

ICPC2, International Classification of Primary Care, second edition;

NCSP, Nordic Classification of Surgical Procedures

Table S2: Moderately predisposing comorbidities or medical therapies Definition of comorbidities and medical therapies that were considered moderately predisposing to severe COVID-19.

Classification system	Codes
Autoimmune disease	
ICD10	D86, K50, K51, L40, M02, M05, M06, M07, M139, M45, M460, M461, M469, M941
Immunosuppressive medication	
ATC	H02AB02, H02AB04, H02AB06, H02AB07, L01BA01, L01XC02, L04AA06, L04AA10, L04AA13, L04AA18, L04AA24, L04AA26, L04AA29, L04AA33, L04AA37, L04AB, L04AC, L04AD01, L04AD02, L04AX01, L04AX03
Neurological condition affecting breathing	
ICD10	G20, G21, G22, G23, G24, G25, G26, G70, G71, G72, G73, G80, G81, G82, G83, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69
Psychotic disease	
ATC	N05AH02
ICD10	F20, F21, F22, F23, F24, F25, F26, F27, F28, F29
ICPC2	P72
Severe chronic liver disease	
ICD10	K702, K703, K704, K71, K72, K73, K74
Severe heart disease	
ICD10	I110, I119, I12, I130, I131, I132, I139, I15, I20, I21, I22, I23, I24, I25, I26, I27, I28, I418, I42, I43, I50
Sleep apnea	
ICD10	G473
NCSP	WX723, WX780
Type 1 diabetes mellitus or adrenal insufficiency	
ATC	A10A
ICD10	E10, E250, E271, E272, E274, E3100, E3101, E3108, E896
ICPC2	T89

ATC, Anatomical Therapeutic Chemical Classification System;
 ICD10, International Statistical Classification of Diseases, tenth revision;
 ICPC2, International Classification of Primary Care, second edition;
 NCSP, Nordic Classification of Surgical Procedures

Table S3: Enrollment of the study cohorts Each target population included all individuals who were living in Finland during the study, met the age criterion at the beginning of the study, and had received at least two monovalent COVID-19 vaccine doses prior to the study.

	No. of individuals
65-to-120-year-olds	
Target population	1222446
Excluded due to hospitalisation due to COVID-19 at the beginning of the study	462
Excluded due to too short dosing interval* prior to the study	8658
Excluded due to bivalent vaccination prior to the study	27
Excluded due to right-censoring prior to the start of individual follow-up	15599
Study cohort	1197700
18-to-64-year-olds with underlying medical conditions	
Target population	450937
Excluded due to hospitalisation due to COVID-19 at the beginning of the study	166–169
Excluded due to too short dosing interval* prior to the study	4075
Excluded due to bivalent vaccination prior to the study	1–4
Excluded due to right-censoring prior to the start of individual follow-up	2009
Study cohort	444683

* less than 91 days between two doses or
less than 14 days between the first two doses (42 days if the first vaccination was with Vaxzevria)

Table S4: Distribution of baseline characteristics Absolute and relative frequencies.

	65-to-120-year-olds	18-to-64-year-olds*
Age in years		
18–34	0 (0%)	65136 (15%)
35–49	0 (0%)	121644 (27%)
50–64	0 (0%)	257903 (58%)
65–79	890950 (74%)	0 (0%)
80–120	306750 (26%)	0 (0%)
Region of residence		
Helsinki-Uusimaa	287242 (24%)	131010 (29%)
Åland	6694 (1%)	1853 (0%)
Northern and Eastern Finland	305597 (26%)	108803 (24%)
Southern Finland	282647 (24%)	94566 (21%)
Western Finland	315520 (26%)	108451 (24%)
Sex		
Female	666396 (56%)	232542 (52%)
Male	531304 (44%)	212141 (48%)
Hospitalized in the year before the study		
No	1046158 (87%)	404221 (91%)
Yes	151542 (13%)	40462 (9%)
Presence of comorbidities or medical therapies		
No predisposing medical conditions	614356 (51%)	0 (0%)
Only moderately predisposing medical conditions	329468 (28%)	316831 (71%)
At least one highly predisposing medical condition	253876 (21%)	127852 (29%)
Long-term care		
No	1162096 (97%)	444266 (100%)
Yes	35604 (3%)	417 (0%)
Number of vaccinations prior to the study		
2	65740 (5%)	88997 (20%)
3	478270 (40%)	297174 (67%)
4–5	653690 (55%)	58512 (13%)
Last infection prior to the study		
No prior infection	1115649 (93%)	326135 (73%)
Pre-Omicron infection	13322 (1%)	14366 (3%)
Omicron infection	68729 (6%)	104182 (23%)

* with underlying medical conditions

Table S5: Hazard ratios, 65-to-120-year-olds Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes and a negative control outcome in 65-to-120-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine.

Days since bivalent vaccination	Cases	Person-years	Hazard ratio		
			MLE	LCI	UCI
Hospitalisation due to COVID-19					
No bivalent vaccination	1466	267657			
0–13	68	23805	0.47	0.36	0.62
14–30	68	27897	0.43	0.33	0.57
31–60	79	44896	0.43	0.33	0.57
61–90	34	24597	0.74	0.50	1.09
91–120	6	3364	1.60	0.69	3.70
121–152	0	105	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	862	267863			
0–13	14	23807	0.20	0.11	0.34
14–30	31	27901	0.39	0.26	0.57
31–60	60	44909	0.57	0.42	0.77
61–90	29	24605	0.74	0.49	1.13
91–120	6	3365	1.33	0.57	3.11
121–152	0	105	NE	NE	NE
Death in which COVID-19 was a contributing factor					
No bivalent vaccination	699	267863			
0–13	6	23807	0.09	0.04	0.21
14–30	30	27901	0.36	0.24	0.54
31–60	48	44909	0.41	0.29	0.57
61–90	19	24605	0.42	0.25	0.69
91–120	7	3365	1.33	0.60	2.94
121–152	0	105	NE	NE	NE
Emergency room visit due to injury					
No bivalent vaccination	7028	205743			
0–13	475	17523	0.87	0.78	0.97
14–30	560	20527	0.92	0.83	1.02
31–60	886	32804	0.96	0.87	1.05
61–90	438	16783	0.96	0.85	1.08
91–120	56–59	2055	1.03	0.79	1.36
121–152	1–4	84	1.97	0.73	5.27

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval;

NE, not estimated

Table S6: Hazard ratios, 65-to-120-year-olds, age-stratified Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes in 65-to-120-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine stratified by age group.

Days since bivalent vaccination	Cases	Person-years	Hazard ratio		
			MLE	LCI	UCI
<i>65-to-79-year-olds</i>					
Hospitalisation due to COVID-19					
No bivalent vaccination	635	187551			
0–13	26	16999	0.46	0.30	0.71
14–60	85	51593	0.63	0.46	0.84
61–120	22	19404	1.08	0.66	1.76
121–152	0	81	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	189	187645			
0–13	7	17000	0.40	0.18	0.90
14–60	19	51602	0.45	0.26	0.78
61–120	8	19410	0.81	0.36	1.82
121–152	0	81	NE	NE	NE
Death in which COVID-19 was a contributing factor					
No bivalent vaccination	170	187645			
0–13	0	17000	NE	NE	NE
14–60	14	51602	0.39	0.20	0.76
61–120	1–4	19410	0.49	0.17	1.45
121–152	0	81	NE	NE	NE
<i>80-to-120-year-olds</i>					
Hospitalisation due to COVID-19					
No bivalent vaccination	831	80106			
0–13	42	6806	0.47	0.32	0.67
14–60	62	21199	0.30	0.21	0.41
61–120	18	8557	0.60	0.35	1.03
121–152	0	24	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	673	80217			
0–13	7	6808	0.13	0.06	0.28
14–60	72	21208	0.50	0.37	0.67
61–120	27	8560	0.78	0.50	1.22
121–152	0	24	NE	NE	NE
Death in which COVID-19 was a contributing factor					
No bivalent vaccination	529	80217			
0–13	6	6808	0.11	0.05	0.26
14–60	64	21208	0.39	0.28	0.53
61–120	22–25	8560	0.50	0.31	0.81
121–152	0	24	NE	NE	NE

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval;

NE, not estimated

Table S7: Hazard ratios, 65-to-120-year-olds, by vaccine composition Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes in 65-to-120-year-olds who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine distinguishing between BA.1 and BA.4-5 bivalent vaccines.

Days since bivalent vaccination	Cases	Person-years	Hazard ratio		
			MLE	LCI	UCI
Hospitalisation due to COVID-19					
No bivalent vaccination	1466	267657			
<i>BA.1 bivalent vaccine</i>					
0–13	18	7313	0.37	0.23	0.60
14–60	37	22865	0.31	0.22	0.45
61–120	17	9684	0.80	0.48	1.32
<i>BA.4-5 bivalent vaccine</i>					
0–13	50	16493	0.53	0.39	0.72
14–60	110	49927	0.50	0.39	0.64
61–120	23	18277	0.82	0.52	1.29
<i>BA.1 and BA.4-5 bivalent vaccines</i>					
121–152	0	105	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	862	267863			
<i>BA.1 bivalent vaccine</i>					
0–13	1–4	7313	0.19	0.07	0.52
14–60	20	22870	0.35	0.22	0.56
61–120	14	9688	0.96	0.55	1.69
<i>BA.4-5 bivalent vaccine</i>					
0–13	10–13	16494	0.20	0.11	0.38
14–60	71	49941	0.55	0.41	0.73
61–120	21	18283	0.70	0.43	1.13
<i>BA.1 and BA.4-5 bivalent vaccines</i>					
121–152	0	105	NE	NE	NE
Death in which COVID-19 was a contributing factor					
No bivalent vaccination	699	267863			
<i>BA.1 bivalent vaccine</i>					
0–13	1–4	7313	0.16	0.05	0.51
14–60	20	22870	0.35	0.22	0.56
61–120	9	9688	0.56	0.28	1.11
<i>BA.4-5 bivalent vaccine</i>					
0–13	1–4	16494	0.06	0.02	0.20
14–60	58	49941	0.41	0.30	0.56
61–120	17	18283	0.48	0.28	0.81
<i>BA.1 and BA.4-5 bivalent vaccines</i>					
121–152	0	105	NE	NE	NE

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval;

NE, not estimated

Table S8: Hazard ratios, 18-to-64-year-olds with underlying medical conditions Covariate-adjusted hazard ratios comparing the hazards of severe COVID-19 outcomes and a negative control outcome in 18-to-64-year-olds with underlying medical conditions who received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-19 vaccine.


Days since bivalent vaccination	Cases	Person-years	Hazard ratio		
			MLE	LCI	UCI
Hospitalisation due to COVID-19					
No bivalent vaccination	216	148379			
0–13	1–4	2520	0.16	0.02	1.15
14–30	5	2881	0.82	0.32	2.07
31–60	10	4465	1.57	0.78	3.15
61–90	7	2478	4.04	1.76	9.26
91–120	1–4	540	5.05	0.67	38.10
121–152	0	23	NE	NE	NE
Death due to COVID-19					
No bivalent vaccination	16	148412			
0–13	0	2520	NE	NE	NE
14–30	0	2882	NE	NE	NE
31–60	0	4466	NE	NE	NE
61–90	0	2479	NE	NE	NE
91–120	0	540	NE	NE	NE
121–152	0	23	NE	NE	NE
Death in which COVID-19 was a contributing factor					
No bivalent vaccination	15	148412			
0–13	0	2520	NE	NE	NE
14–30	1–4	2882	NE	NE	NE
31–60	1–4	4466	NE	NE	NE
61–90	0	2479	NE	NE	NE
91–120	0	540	NE	NE	NE
121–152	0	23	NE	NE	NE
Emergency room visit due to injury					
No bivalent vaccination	1984	104301			
0–13	43	1757	1.38	1.00	1.89
14–30	47	2013	1.38	1.02	1.87
31–60	63	3104	1.26	0.96	1.65
61–90	30	1636	1.22	0.84	1.78
91–120	6	334	1.21	0.54	2.73
121–152	0	17	NE	NE	NE

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval;

NE, not estimated

Figure S1: Distribution of sequenced Omicron lineages in Finland The graph shows the percentages of the most frequent SARS-CoV-2 sublineages detected by sentinel surveillance and recorded in the National Infectious Diseases Register by week of sample collection since August 2022. Green bars represent BA.2 sublineages (BA.2 lineages, BA.2.75.X and BA.2.3.20.X), orange bars represent BA.4 sublineages (BA.4 lineages and BA.4.6.X) and pink bars represent BA.5 sublineages (BA.5 lineages, BF.7.X and BQ.1.X). The black bars represent sublineages that descended from the XBB recombinant lineage and the group ‘Other variants’ represents sublineages not assigned to any of the previous groups. The .X extension covers the whole sublineage family, e.g. BQ.1.X covers all descendants of BQ.1, such as BQ.1.1 and BQ.1.2.



Adapted from <https://thl.fi/fi/web/infektiotaudit-ja-rokotukset/ajankohtaista/ajankohtaista-koronaviruksesta-covid-19/muuntuneet-koronavirukset/sars-cov-2-koronaviruksen-genomiseuranta>